Navigation Links
HGS announces positive Phase 2 LymphoStat-B at ACR meeting
Date:11/9/2007

ROCKVILLE, Maryland November 9, 2007 Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the presentation of Phase 2 clinical results demonstrating that LymphoStat-B (belimumab) achieved a sustained improvement in disease activity across multiple clinical measures, decreased the frequency of disease flares over time, and was well tolerated through 2.5 years on treatment in combination with standard of care in patients with active systemic lupus erythematosus (SLE). The results will be the subject of an oral presentation today in Boston at the Annual Scientific Meeting of the American College of Rheumatology (ACR).

SLE is a chronic disease, and patients need new therapies that provide durable efficacy with a favorable safety profile, said Michelle A. Petri, M.D., M.P.H., Professor, Division of Rheumatology, Department of Medicine, Johns Hopkins University. The Phase 2 results presented at ACR showed that the significant clinical benefit observed for LymphoStat-B in serologically active SLE patients at 52 weeks appears to be sustained through 2.5 years. We look forward to further evaluation of LymphoStat-B in larger Phase 3 studies, which are ongoing.

A separate poster presentation of the safety profile of LymphoStat-B showed that LymphoStat-B was well tolerated in combination with SLE standard-of-care therapy during long-term exposure, with incidence rates of adverse events, serious adverse events, malignancies, infections and laboratory abnormalities remaining comparable to placebo or decreasing through 2.5 years of treatment (Merrill et al).

The results through 2.5 years confirm and extend the results reported at Weeks 52 and 76, said David C. Stump, M.D., Executive Vice President, Research and Development, HGS. At Week 52 in LymphoStat-B patients with active SLE, we saw significant reductions in SLE disease activity versus placebo as measured by the SELENA SLEDAI and BILAG indices, the Physicians Global Assessment,
'/>"/>

Contact: Jerry Parrot
Jerry_Parrott@hgsi.com
301-315-2777
Edelman Public Relations
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
2. LaserCard Corporation Announces Expansion of Middle East Project
3. BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution
4. Balzan Foundation announces 2007 winners
5. The American Society of Plant Biologists announces 2007 awards
6. ASPB announces Summer Undergraduate Research Fellowship 2007 recipients
7. NIST announces 56 new awards for innovative technology research and development
8. Titanium Group Announces Contract With Haitong Securities
9. Measurement Specialties, Inc. Announces Impact of German Business Tax Reform 2008 Resulting in Lower Combined German Tax Rate - Impacts 2Q08 Reported Financial Results
10. FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change
11. Positive results for airway bypass
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2014)...   3D scanner ... Fuel3D , a developer of 3D scanning solutions, ... $6.4 million (£4 million). This funding builds on the company,s ... and paves the way for the commercial launch of the ... round was led by Chimera Partners and will be used ...
(Date:11/3/2014)... study published in this month,s Proceedings of ... of a recently discovered communication molecule of the body,s ... known to limit inflammation and the current study reports ... the ability of the immune system to recognize and ... IL-37,s effect on the immune system now allows us ...
(Date:11/2/2014)... 2014)—In support of a bold quest to rid the ... Foundation today announced an award of US$156 million to ... in building new vaccines that will interrupt the cycle ... to zero" agenda. Such vaccines would ensure that parasite ... an "immunological bed net." , This approach to ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3PNAS: From HIV to cancer, IL-37 regulates immune system 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4
... (Dec. 5, 2013) A new method to identify ... speed the process of novel drug design, according to ... computational techniques and experimental data helped Rice theorists predict ... hard to detect. The work should be ...
... on a shark" is the take home message from an ... Ritter of the Shark Research Institute and Raid Amin of ... sharks can comprehend body orientation and therefore know whether humans ... approach and possibly attack their prey from the blind side ...
... effectively implement the well-known double-stranded structure and the elasticity ... by Jae-Hyung Jeon and Wokyung Sung of Pohang University ... in an effort to more comprehensively explore the nucleic ... published in Springer,s Journal of Biological Physics . ...
Cached Biology News:Proteins' passing phases revealed 2Proteins' passing phases revealed 3Sharks prefer to sneak up from behind, study shows 2DNA helicity and elasticity explained on the nanoscale 2
(Date:11/21/2014)... Washington, USA (PRWEB) November 19, 2014 ... in our lives was shared with more than 200 ... and postgraduate students from the University of Otago Physics ... Grant . The Otago students, members of the university’s ... New Zealand in early September, giving children from small, ...
(Date:11/21/2014)... The report, "Synthetic Biology Market ... kits), Technology (Bioinformatics, Nanotechnology, Gene Synthesis, Cloning ... - Global Forecast to 2018", analyses and ... and challenges. , Browse 99 market data ... pages and in-depth TOC of the global ...
(Date:11/21/2014)... 21, 2014 2014 Deep Research ... is a professional and in-depth research report on ... information, like its definition, classification, application, and ... This report covers the international market analysis, including ... as the US, Europe, Asia, China, Japan etc. ...
(Date:11/21/2014)... and SAN DIEGO , Nov. ... today announced that President and CEO Marc Hedrick , M.D. ... DATE:   Thursday, December 4, 2014 TIME:    ... here or paste this URL into your browser,s ... that investors pre-register to save time and receive event updates. ...
Breaking Biology Technology:Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4
... 21 Richter-Helm,BioLogics GmbH & Co. KG and ... development and manufacturing of Athera,s novel product for,prevention ... the,protein, Annexin A5, to endothelium. The recombinant protein ... with Acute Coronary Syndrome and who,are at imminent ...
... YORK, Jan. 20 Immtech Pharmaceuticals, Inc. (NYSE ... has appointed Virchow, Krause & Company, LLP as ... The decision to change the Company,s independent registered ... board of directors. The appointment will result ...
... - Vasogen Inc. (NASDAQ: VSGN ; TSX:VAS) today ... on January 13, 2009, indicating that it no longer ... in Nasdaq Marketplace Rule 4350(c)(1) (the "Rule"). The letter ... which was announced publicly in a January 6, 2009 ...
Cached Biology Technology:Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease 2Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease 3Immtech Announces Appointment of Virchow Krause as Independent Registered Public Accounting Firm 2Vasogen Complies with NASDAQ Marketplace Rule 4350(c)(1) 2
...
...
... is the most advanced thermal cycler ever ... performance, the Dyad also boasts graphical programming ... navigation via touch pad or mouse. ... economically expanded to a four-bay system with ...
... The TRAPeze RT Telomerase ... sensitive in vitro assay for ... time quantification of telomerase activity. ... original TRAPeze assay and adds ...
Biology Products: